Evidence map›Paper›PMID 35787841›Full record

ArticlePreventive medicine2022

Use of heated tobacco products, moderate alcohol drinking, and anti-SARS-CoV-2 IgG antibody titers after BNT162b2 vaccination among Japanese healthcare workers.

Shohei Yamamoto, Akihito Tanaka, Norio Ohmagari, Koushi Yamaguchi, Kazue Ishitsuka, Naho Morisaki, Masayo Kojima, Akihiko Nishikimi, Haruhiko Tokuda, Manami Inoue and 7 more

Open access · hybridAbstract read
In one paragraph

Article in Preventive medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 32 citations in OpenAlex.

  1. Herpes zoster vaccination and cognitive disorders in older adults.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. How does geographical diversity shape vaccine efficacy?Clinical and experimental vaccine research · 2024
    Review
  9. Vaccinomics and adversomics: key elements for a personalized vaccinology.Clinical and experimental vaccine research · 2024
    Review
  10. Article
  11. Observational
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 1 country.

Shohei YamamotoDepartment of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan. Electronic address: syamamoto@hosp.ncgm.go.jp.
Akihito TanakaDepartment of Laboratory Testing, Center Hospital of the National Center for the Global Health and Medicine, Tokyo, Japan.
Norio OhmagariDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Koushi YamaguchiCenter of Maternal-Fetal, Neonatal and Reproductive Medicine, National Center for Child Health and Development, Tokyo, Japan.
Kazue IshitsukaDepartment of social science, National Research Institute for Child Health and Development, Tokyo, Japan.
Naho MorisakiDepartment of social science, National Research Institute for Child Health and Development, Tokyo, Japan.
Masayo KojimaDepartment of Frailty Research, Research Institute, National Center for Geriatrics and Gerontology, Aichi, Japan.
Akihiko NishikimiBiosafety Division, Research Institute, National Center for Geriatrics and Gerontology, Aichi, Japan.
Haruhiko TokudaBioresource Division, Research Institute, National Center for Geriatrics and Gerontology, Aichi, Japan.
Manami InoueDivision of Prevention, National Cancer Center Institute for Cancer Control, Tokyo, Japan; Division of Cohort Research, National Cancer Center Institute for Cancer Control, Tokyo, Japan.
Shiori TanakaDivision of Prevention, National Cancer Center Institute for Cancer Control, Tokyo, Japan.
Jun UmezawaDivision of Prevention, National Cancer Center Institute for Cancer Control, Tokyo, Japan.
Ryo OkuboClinical Research & Education Promotion Division, National Center of Neurology and Psychiatry, Tokyo, Japan.
Kunihiro NishimuraDepartment of Preventive Medicine and Epidemiology, National Cerebral and Cardiovascular Center, Osaka, Japan.
Maki KonishiDepartment of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
Kengo MiyoCenter for Medical Informatics Intelligence, National Center for Global Health and Medicine, Tokyo, Japan.
Tetsuya MizoueDepartment of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
National Center for Global Health and Medicine · JPNational Center For Child Health and Development · JPNational Center for Geriatrics and Gerontology · JPNational Center of Neurology and Psychiatry · JPNational Cerebral and Cardiovascular Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The effect of heated tobacco products (HTPs) use and moderate alcohol drinking on immunogenicity to coronavirus disease (COVID-19) vaccines remain elusive. This study aimed to examine the association of tobacco product use and alcohol consumption with anti-SARS-CoV-2 spike IgG antibody titers after the BNT162b2 vaccine. Participants were 3433 healthcare workers receiving two vaccine doses in the 4 national centers for advanced medical and research in Japan. Smoking status and alcohol consumption were assessed via a questionnaire, and anti-SARS-CoV-2 spike IgG titers were measured with chemiluminescent enzyme immunoassay using serum collected on the median of 64 days after the second vaccination. Multilevel linear regression models were used to estimate the geometric mean titers (GMT) and the ratios of means (RoM) between groups with adjustment for covariates. Compared with never-smokers (GMT = 118), IgG antibody titers were significantly lower among HTPs users (including those who also smoked cigarettes) (GMT = 105; RoM = 0.89 [95%CI: 0.78-0.99]) and exclusive cigarettes smokers (GMT = 98; RoM = 0.81 [95%CI: 0.71-0.92]). Compared with non-drinkers of alcohol (GMT = 123), alcohol drinkers consuming <1 go/day (GMT = 113; RoM = 0.93 [95%CI: 0.88-0.98]), 1-1.9 go/day (GMT = 104; RoM = 0.85 [95%CI: 0.78-0.93]), and ≥ 2 go/day (GMT = 103; RoM = 0.84 [95%CI: 0.74-0.96]) had significantly lower antibody titers (P for trend<0.01). Spline analysis showed a large reduction of antibody until around 1 go/day of alcohol consumption, and then they gradually decreased. Results suggest that in addition to conventional cigarette smoking and heavy alcohol drinking, HTPs use and moderate alcohol drinking may be predictors of lower immunological response to COVID-19 vaccine.

Indexed as

COVID-19Tobacco ProductsAlcohol DrinkingBNT162 VaccineCOVID-19 VaccinesHealth PersonnelHumansImmunoglobulin GJapanVaccinationBNT162 VaccineCOVID-19 VaccinesImmunoglobulin GAlcohol consumptionCOVID-19Heated tobacco productsImmunogenicitySmokingVaccine

Identifiers

PMID35787841
PMCPMC9249408
OpenAlexW4283774167

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.